Racing fans, rejoice — the 2025 Dirt Late Model season is set to begin with the annual Wild West Shootout at Vado Speedway Park in New Mexico. The 2025 Wild West Shootout, which offers a total ...

Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin G1(IgG1) antibody, MTX-463, into a Phase II trial for the treatment of ...

Get Real-Time News and Alerts for Your Portfolio Medicare drug plans can now cover Eli Lilly ... and treatment-regimen estimands and demonstrated a mean reduction of up to 62.8% on the apnea ...

in paragraph 8) China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the United States, Japan and the UK, Lilly said in a statement.

The partnership aims to address unmet clinical needs in the treatment of hematologic cancers and expand patient access to innovative therapies. In other developments, Eli Lilly's weight loss drug ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY and Novo Nordisk NVO stock. As the major players in the hyper-scale ...

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and delivering life-changing medicines to address some of the world's most pressin ...

in paragraph 8) (Reuters) - China's medical regulator has approved Eli Lilly (NYSE:LLY)'s treatment for early Alzheimer's, providing patients with another option after Eisai and Biogen's Leqembi ...

(Reuters) - China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option after Eisai and Biogen's Leqembi received approval in January ...

(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend approval for Biogen's drug, Leqembi, in paragraph 8) (Reuters) - China's medical ...

The Food and Drug Administration on Friday cleared Eli Lilly’s obesity drug Zepbound as the first treatment for a common sleep disorder in the U.S. Zepbound, whose scientific name is tirzepatide ...